RXRX vs IMCR
Comparison between Recursion Pharmaceuticals Inc - Class A (RXRX, Company) and Immunocore Holdings plc (IMCR, Company).
Both RXRX and IMCR are from the Healthcare sector.
5-Year PerformanceIMCR has outperformed RXRX, delivering a return of +1.2% compared to -35.3%
RXRX vs IMCR - Performance Comparison
Key Characteristics
Financial metrics and valuation ratios
RXRX vs IMCR - Historical Returns
Returns include dividend reinvestment.
RXRX vs IMCR - Annual Returns (2021 - 2026)
Returns include dividend reinvestment.
| Year | RXRX | IMCR |
|---|---|---|
| 2026 | -23.33% | +0.65% |
| 2025 | -43.27% | +16.40% |
| 2024 | -31.51% | -58.82% |
| 2023 | +30.60% | +23.28% |
| 2022 | -57.24% | +66.43% |
| 2021 | -45.27% | -20.74% |
RXRX vs IMCR Drawdown Comparison
The maximum drawdown for RXRX was -93.13%, occurring on Mar 30, 2026. This drawdown has not yet recovered.
The maximum drawdown for IMCR was -67.45%, occurring on Apr 8, 2025. This drawdown has not yet recovered.
The current RXRX drawdown is -92.21%. The current IMCR drawdown is -54.88%.
| Rank | RXRX | IMCR |
|---|---|---|
| #1 | -93.13% Jul 13, 2021 - Mar 30, 2026 | -67.45% Feb 7, 2024 - Apr 8, 2025 |
| #2 | -38.10% Apr 29, 2021 - Jun 17, 2021 | -66.38% Feb 8, 2021 - Sep 8, 2022 |
| #3 | -10.54% Apr 16, 2021 - Apr 21, 2021 | -35.66% Aug 1, 2023 - Dec 26, 2023 |
| #4 | -10.45% Jun 21, 2021 - Jul 6, 2021 | -29.81% Feb 13, 2023 - Jul 28, 2023 |
| #5 | -8.29% Apr 21, 2021 - Apr 29, 2021 | -29.70% Sep 8, 2022 - Oct 25, 2022 |
| #6 | N/A | -20.97% Nov 15, 2022 - Feb 13, 2023 |
| #7 | N/A | -8.33% Jan 11, 2024 - Feb 1, 2024 |
| #8 | N/A | -7.10% Jan 2, 2024 - Jan 9, 2024 |
| #9 | N/A | -4.61% Oct 25, 2022 - Nov 11, 2022 |
| #10 | N/A | -1.95% Feb 1, 2024 - Feb 7, 2024 |
| #11 | N/A | -1.70% Dec 27, 2023 - Jan 2, 2024 |
| #12 | N/A | -1.33% Jan 9, 2024 - Jan 11, 2024 |
Correlation
Correlation between RXRX and IMCR is 0.07 which considered as a very weak or no correlation - the stocks move independently of each other.
Select Stocks to Compare
More Comparisons
Compare with similar stocks